Topical Interferon Alfa-2b for the Treatment of Recalcitrant Ocular Surface Squamous Neoplasia

Holcombe, David J.; Lee, Graham

doi:10.1016/j.ajo.2006.05.058

Cited by 47 publications

(35 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While 72% responded to IFNα2b, patients with invasive disease required local injections and/or surgery. In another series of 10 patients with OSSN, one required exenteration likely because topical therapy delayed definitive diagnosis and treatment of squamous cell carcinoma [20]. Those authors concluded that topical IFNα2b by itself is contraindicated if invasive disease is present.…”

Section: Discussionmentioning

confidence: 99%

Widespread Ocular Surface Squamous Neoplasia Treated with Topical Interferon Alpha-2b

et al. 2018

View full text Add to dashboard Cite

Purpose: To emphasize the importance of staging ocular surface squamous neoplasia when contemplating use of topical interferon alpha-2b alone. Cases: Two patients with 360 degrees of limbal involvement. Results: Two patients with in situ squamous cell carcinoma of the conjunctiva and clinical involvement of the entire limbus were treated with topical interferon alpha-2b. Thorough examination and multiple biopsies excluded invasive disease. The patients had complete response to therapy. Conclusion: Widespread intraepithelial squamous neoplasia involving the entire limbus can be successfully treated with topical therapies. Biopsy plays a role in excluding invasive disease. Interferon alpha-2b is a preferable agent to start with because it is well tolerated. Since long-term risks of recurrence are unknown, appropriate monitoring is essential.

show abstract

Section: Discussionmentioning

confidence: 99%

Widespread Ocular Surface Squamous Neoplasia Treated with Topical Interferon Alpha-2b

et al. 2018

View full text Add to dashboard Cite

show abstract

“…35 Our study showed similar rates of self-resolving complications. In one study, 24 57% of treated patients developed conjunctival hyperemia and follicular conjunctivitis, most likely attributed to the vehicle (benzyl alcohol, glycine, and human albumin) used to deliver interferon alfa-2b. The vehicle in our preparation was sterile distilled water, and our rate of conjunctival hyperemia was 10% (2 patients), with no cases of follicular conjunctivitis and 10% (2 patients) with follicular hypertrophy.…”

Section: Commentmentioning

confidence: 97%

Topical Interferon Alfa-2b for Management of Ocular Surface Squamous Neoplasia in 23 Cases

Shah

Kaliki²,

Kim³

et al. 2012

Arch Ophthalmol

View full text Add to dashboard Cite

Objective: To evaluate the efficacy of topical interferon alfa-2b in the management of ocular surface squamous neoplasia (OSSN).Methods: Clinically visible OSSN in 20 patients (23 tumors) was managed with topical interferon alfa-2b, 1 million IU/mL, 4 times daily. Tumor control and complications were evaluated according to American Joint Committee on Cancer classification.Results: Complete tumor resolution was achieved in 19 tumors (83%) following topical interferon alfa-2b treatment for a median period of 6 months (mean, 7 months; range, 1-12 months) and maintained for up to 24 months of follow-up. Of the 4 tumors with partial resolution (17%), tumor surface area was reduced 44% (median) during 4 months (median) without further response and alternative therapy was used. Based on American Joint Committee on Cancer classification, complete control was achieved in 2 of 3 Tis (67%), 17 of 20 T3 (85%), 19 of 23 N0 (83%), and 19 of 23 M0 (83%) category tumors. Tumors involving the cornea responded earlier compared with those without corneal involvement (P=.01). Initial tumor size did not correlate with time to response (P=.27). Recurrence was noted in 1 case (Tis, 4%) at 3 months. Adverse effects included conjunctival hyperemia (2 [10%]), follicular hypertrophy (2 [10%]), giant papillary conjunctivitis (1 [5%]), irritation (1 [5%]), corneal epithelial defect (1 [5%]), and flulike symptoms (1 [5%]); all resolved within 1 month of medication discontinuation. Conclusion:According to American Joint Committee on Cancer classification, complete control with topical interferon alfa-2b can be achieved in 67% of Tis, 85% of T3, and 83% of all OSSN.

show abstract

“…10,11 Various topical agents have been advocated, including topical treatment with mitomycin C, 12 5-fluorouracil, 13 and interferon >-2b (IFN>2b). 14,15 In this study, we have evaluated topical IFN>2b as a single therapy for primary OSSN and analyzed the outcomes and complications.…”

mentioning

confidence: 99%

Topical Interferon α-2b as a Single Therapy for Primary Ocular Surface Squamous Neoplasia

Kusumesh

Ambastha²,

Sinha³

et al. 2015

Asia-Pacific Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

Topical Interferon Alfa-2b for the Treatment of Recalcitrant Ocular Surface Squamous Neoplasia

Cited by 47 publications

References 14 publications

Widespread Ocular Surface Squamous Neoplasia Treated with Topical Interferon Alpha-2b

Widespread Ocular Surface Squamous Neoplasia Treated with Topical Interferon Alpha-2b

Topical Interferon Alfa-2b for Management of Ocular Surface Squamous Neoplasia in 23 Cases

Topical Interferon α-2b as a Single Therapy for Primary Ocular Surface Squamous Neoplasia

Contact Info

Product

Resources

About